Sugi Predict

Sugi Predict / Compounds / SCHEMBL270660

SCHEMBL270660

SCHEMBL270660

Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1ccc(C(F)(F)F)cc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ JAK3 P52333 7/20 0.72
▸ JAK2 O60674 7/20 0.72
▸ BRD4 O60885 6/20 0.72
▸ JAK1 P23458 6/20 0.72
▸ HDAC1 Q13547 3/20 0.72
▸ TYK2 P29597 3/20 0.72
▸ RET P07949 2/20 0.72
▸ FLT3 P36888 2/20 0.72
▸ HDAC8 Q9BY41 1/20 0.72
▸ HDAC6 Q9UBN7 1/20 0.72
▸ BRDT Q58F21 2/20 0.65
▸ BRD2 P25440 1/20 0.65
▸ BRD3 Q15059 1/20 0.65
▸ AXL P30530 4/20 0.63
▸ SRC P12931 4/20 0.63
▸ BRAF P15056 2/20 0.63
▸ MERTK Q12866 2/20 0.63
▸ PTK2 Q05397 2/20 0.63
▸ LCK P06239 2/20 0.63
▸ KDR P35968 2/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL264080 0.99 JAK3 (0.71) JAK3JAK2BRD4JAK1HDAC1
SCHEMBL264515 0.91 BRD4 (0.71) JAK3JAK2BRD4JAK1HDAC1
SCHEMBL269991 0.89 JAK1 (0.75) JAK3JAK2BRD4JAK1HDAC1
Hydrochloric Acid SCHEMBL265421 0.88 JAK1 (0.74) JAK3JAK2BRD4JAK1HDAC1
SCHEMBL265437 0.88 JAK3 (0.74) JAK3JAK2BRD4JAK1HDAC1
SCHEMBL28677225 0.87 BRD4 (0.73) JAK3JAK2BRD4JAK1HDAC1
SCHEMBL270326 0.87 BRD4 (0.73) JAK3JAK2BRD4JAK1HDAC1
SCHEMBL265703 0.86 BRD4 (0.63) JAK3JAK2BRD4JAK1HDAC1
SCHEMBL12278161 0.86 JAK1 (0.71) JAK3JAK2BRD4JAK1HDAC1
SCHEMBL265787 0.85 BRD4 (0.70) JAK3JAK2BRD4JAK1HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1951684-B1 BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES TARGEGEN INC (US) 2016-07-13 — — EP disclosed
US-8138199-B2 Use of bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2012-03-20 — — US disclosed
US-8138199-B2 Use of bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2012-03-20 — — US disclosed
US-8133900-B2 Use of bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2012-03-13 — — US disclosed
US-8133900-B2 Use of bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2012-03-13 — — US disclosed
US-20110269721-A1 METHODS OF TREATING THALASSEMIA TARGEGEN, INC. (US) 2011-11-03 — — US disclosed
US-20110212077-A1 BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES TARGEGEN, INC. (US) 2011-09-01 — — US disclosed
US-7825246-B2 Bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2010-11-02 — — US disclosed
US-7825246-B2 Bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2010-11-02 — — US disclosed
WO-2010017122-A2 METHODS OF TREATING THALASSEMIA TARGEGEN INC. (US) 2010-02-11 — — WO disclosed
US-20090286789-A1 Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases TARGEGEN, INC. (US) 2009-11-19 — — US disclosed
US-20090275582-A1 Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases IMPACT BIOMEDICINES, INC. 2009-11-05 — — US disclosed
US-20090275582-A1 Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases IMPACT BIOMEDICINES, INC. 2009-11-05 — — US disclosed
US-7528143-B2 Bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2009-05-05 — — US disclosed
US-7528143-B2 Bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2009-05-05 — — US disclosed
US-20070259904-A1 Bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2007-11-08 — — US disclosed
US-20070259904-A1 Bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2007-11-08 — — US disclosed
US-20070191405-A1 Bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2007-08-16 — — US disclosed
US-20070191405-A1 Bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2007-08-16 — — US disclosed
WO-2007053452-A1 BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES TARGEGEN, INC. (US) 2007-05-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286789-A1 Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases JAK2, TYK2, LTK JAK3 4/4885JAK2 1/4885BRD4 156/4885
US-20070191405-A1 Bi-aryl meta-pyrimidine inhibitors of kinases JAK2, TYK2, JAK3 JAK3 3/4885JAK2 1/4885BRD4 142/4885
US-20070259904-A1 Bi-aryl meta-pyrimidine inhibitors of kinases JAK2, TYK2, JAK3 JAK3 3/4885JAK2 1/4885BRD4 142/4885
US-20090275582-A1 Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases JAK2, TYK2, JAK3 JAK3 3/4885JAK2 1/4885BRD4 142/4885
US-20110212077-A1 BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES JAK2, TYK2, JAK3 JAK3 3/4885JAK2 1/4885BRD4 142/4885
US-20110269721-A1 METHODS OF TREATING THALASSEMIA JAK2, STAT5A, STAT5B JAK3 5/4885JAK2 1/4885BRD4 1036/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.